(Q54432514)

29 May 2018

title

New 4-quinolones in the treatment of urinary tract infections. (English)

1 reference

29 May 2018

0 references

Boerema JB

1

1 reference

29 May 2018

publication date

1 February 1986

1 reference

29 May 2018

Pharmaceutisch weekblad. Scientific edition

published in

1 reference

29 May 2018

volume

8

1 reference

29 May 2018

issue

1

1 reference

29 May 2018

page(s)

46-52

1 reference

29 May 2018

Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF01975480

In vitro activity of ciprofloxacin (Bay o 9867)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975480

In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975480

The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975480

The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975480

Treatment of simple urinary tract infections in general practice with a 3-day course of norfloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975480

Norfloxacin, amoxycillin, cotrimoxazole and nalidixic acid: A summary of 3-day and 7-day therapy studies in the treatment of urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975480

Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975480

Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975480

Staphylococcus saprophyticus: a frequent cause of acute urinary tract infection among female outpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975480

The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975480

A review of the problem of urinary infection management and the evaluation of a potential new antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975480

Comparative study using norfloxacin and amoxycillin in the treatment of complicated urinary tract infections in geriatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975480

Elimination of plasmids by new 4-quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975480

Urinary Tract Infections Caused by Staphylococcus Saprophyticus: Recurrences and Complications

21 January 2018

1 reference

12 December 2020

The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.

1 reference

12 December 2020

Ciprofloxacin distribution in prostatic tissue and fluid following oral administration

1 reference

12 December 2020

Resistance to ciprofloxacin.

1 reference

12 December 2020

Sensitivity of urinary staphylococci to ciprofloxacin and acrosoxacin

1 reference

12 December 2020

Intraprostatic concentrations of ciprofloxacin after intravenous administration

1 reference

12 December 2020

Experiences on the efficacy and safety of nalidixic acid, oxolinic acid, cinoxacin and norfloxacin in the treatment of urinary tract infections (UTI)

1 reference

12 December 2020

Significance of asymptomatic bacterium in neurogenic bladder disease

1 reference

12 December 2020

Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections.

1 reference

12 December 2020

A Critical Evaluation of Nalidixic Acid in Urinary-Tract Infections

1 reference

12 December 2020

Resistance to nalidixic acid. A misconception due to underdosage.

1 reference

12 December 2020

The in-vitro comparative activity of quinolones against bacteria from urinary tract infections in general practice.

1 reference

12 December 2020

Norfloxacin for the treatment of uncomplicated urinary tract infections

1 reference

12 December 2020

A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly

1 reference

12 December 2020

Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

1 reference

12 December 2020

Treatment of acute urinary infection by norfloxacin or nalidixic acid/citrate: a multi-centre comparative study

1 reference

12 December 2020

Mutational resistance to 4-quinolone antibacterial agents

1 reference

12 December 2020

In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.

1 reference

12 December 2020

Norfloxacin versus cotrimoxazole in the treatment of lower urinary tract infections

1 reference

12 December 2020

In-vitro studies with ciprofloxacin, a new 4-quinolone compound.

1 reference

12 December 2020

In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid

1 reference

12 December 2020

Ciprofloxacin-resistant staphylococci

1 reference

12 December 2020

Diffusion of Antibiotics from Plasma into Prostatic Fluid

1 reference

12 December 2020

Ciprofloxacin-resistant Staphylococcus aureus

1 reference

12 December 2020

Norfloxacin versus cotrimoxazole in the treatment of uncomplicated urinary tract infections--a multi-centre trial

1 reference

12 December 2020

Clinical evaluation of norfloxacin versus cotrimoxazole in urinary tract infections

1 reference

12 December 2020

Bactericidal intraprostatic concentrations of norfloxacin

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01975480

1 reference

29 May 2018

1 reference

29 May 2018